Table 14.8

De Novo Posttransplant Solid Malignancy, 1995 to 2004

Liver Recipients

Malignancies by Type Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Total # of Post-Tx Malignancies 209 194 202 207 196 131 113 99 50 20
Squamous/Basal Cell Carcinoma 87 77 81 69 68 48 38 34 14 10
Melanoma 1 6 9 2 9 2 2 2 1 -
Kaposi Sarcoma 2 - - - 5 2 1 2 - 1
Central Nervous System 1 2 1 5 - 1 - 2 - -
Genito-Urinary (1) 21 19 21 31 12 16 8 3 4 -
Gastro-Intestinal (2) 19 28 28 32 29 13 15 7 7 3
Primary Hepatic Tumor 3 8 5 13 11 12 6 10 6 -
Metastatic Hepatic Tumor 2 5 6 8 4 4 8 8 6 1
Larynx/Bronchi/Lung 35 27 18 32 23 17 18 18 3 2
Breast/Thyroid 13 7 12 4 14 3 5 5 2 1
Leukemia 4 2 3 2 - - - - 1 1
Sarcoma (3) 2 - - - - 1 - 2 2 -
Other 13 11 11 7 13 10 8 4 3 1
Unknown 6 2 7 2 8 2 4 2 1 -
Squamous/Basal Cell Carcinoma 41.6% 39.7% 40.1% 33.3% 34.7% 36.6% 33.6% 34.3% 28.0% 50.0%
Melanoma 0.5% 3.1% 4.5% 1.0% 4.6% 1.5% 1.8% 2.0% 2.0% -
Kaposi Sarcoma 1.0% - - - 2.6% 1.5% 0.9% 2.0% - 5.0%
Central Nervous System 0.5% 1.0% 0.5% 2.4% - 0.8% - 2.0% - -
Genito-Urinary (1) 10.0% 9.8% 10.4% 15.0% 6.1% 12.2% 7.1% 3.0% 8.0% -
Gastro-Intestinal (2) 9.1% 14.4% 13.9% 15.5% 14.8% 9.9% 13.3% 7.1% 14.0% 15.0%
Primary Hepatic Tumor 1.4% 4.1% 2.5% 6.3% 5.6% 9.2% 5.3% 10.1% 12.0% -
Metastatic Hepatic Tumor 1.0% 2.6% 3.0% 3.9% 2.0% 3.1% 7.1% 8.1% 12.0% 5.0%
Larynx/Bronchi/Lung 16.7% 13.9% 8.9% 15.5% 11.7% 13.0% 15.9% 18.2% 6.0% 10.0%
Breast/Thyroid 6.2% 3.6% 5.9% 1.9% 7.1% 2.3% 4.4% 5.1% 4.0% 5.0%
Leukemia 1.9% 1.0% 1.5% 1.0% - - - - 2.0% 5.0%
Sarcoma (3) 1.0% - - - - 0.8% - 2.0% 4.0% -
Other 6.2% 5.7% 5.4% 3.4% 6.6% 7.6% 7.1% 4.0% 6.0% 5.0%
Unknown 2.9% 1.0% 3.5% 1.0% 4.1% 1.5% 3.5% 2.0% 2.0% -
Total # of Patients 148 147 154 158 154 111 95 86 43 18


Source: OPTN/SRTR Data as of May 2, 2005.

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.